Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
DA-1241 by NeuroBo Pharmaceuticals for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
DA-1241 is under clinical development by NeuroBo Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...